Literature DB >> 23765230

Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.

Tilman Schlothauer1, Petra Rueger, Jan Olaf Stracke, Hubert Hertenberger, Felix Fingas, Lothar Kling, Thomas Emrich, Georg Drabner, Stefan Seeber, Johannes Auer, Stefan Koch, Apollon Papadimitriou.   

Abstract

The neonatal Fc receptor (FcRn) is important for the metabolic fate of IgG antibodies in vivo. Analysis of the interaction between FcRn and IgG in vitro might provide insight into the structural and functional integrity of therapeutic IgG that may affect pharmacokinetics (PK) in vivo. We developed a standardized pH gradient FcRn affinity liquid chromatography method with conditions closely resembling the physiological mechanism of interaction between IgG and FcRn. This method allows the separation of molecular IgG isoforms, degradation products and engineered molecules based on their affinity to FcRn. Human FcRn was immobilized on the column and a linear pH gradient from pH 5.5 to 8.8 was applied. FcRn chromatography was used in comparison to surface plasmon resonance to characterize different monoclonal IgG preparations, e.g., oxidized or aggregated species. Wild-type and engineered IgGs were compared in vitro by FcRn chromatography and in vivo by PK studies in huFcRn transgenic mice. Analytical FcRn chromatography allows differentiation of IgG samples and variants by peak pattern and retention time profile. The method can distinguish: 1) IgGs with different Fabs, 2) oxidized from native IgG, 3) aggregates from monomer and 4) antibodies with mutations in the Fc part from wild-type IgGs. Changes in the FcRn chromatographic behavior of mutant IgGs relative to the wild-type IgG correlate to changes in the PK profile in the FcRn transgenic mice. These results demonstrate that FcRn affinity chromatography is a useful new method for the assessment of IgG integrity.

Entities:  

Keywords:  FcRn; PK; affinity chromatography; antibody; column; degradation; methionine oxidation; neonatal Fc receptor; pH gradient; pharmacokinetics

Mesh:

Substances:

Year:  2013        PMID: 23765230      PMCID: PMC3906311          DOI: 10.4161/mabs.24981

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  39 in total

Review 1.  Development trends for human monoclonal antibody therapeutics.

Authors:  Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal:  Nat Rev Drug Discov       Date:  2010-09-03       Impact factor: 84.694

2.  Progressive lengthening of 3' untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic development.

Authors:  Zhe Ji; Ju Youn Lee; Zhenhua Pan; Bingjun Jiang; Bin Tian
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

3.  Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.

Authors:  Weirong Wang; Josef Vlasak; Yunsong Li; Pavlo Pristatsky; Yulin Fang; Tamara Pittman; Jeanette Roman; Yang Wang; Thomayant Prueksaritanont; Roxana Ionescu
Journal:  Mol Immunol       Date:  2011-01-21       Impact factor: 4.407

4.  Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.

Authors:  Joey Pollastrini; Thomas M Dillon; Pavel Bondarenko; Robert Y-T Chou
Journal:  Anal Biochem       Date:  2011-03-06       Impact factor: 3.365

5.  Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule
Journal:  Methods Mol Biol       Date:  2010

6.  Enhanced antibody half-life improves in vivo activity.

Authors:  Jonathan Zalevsky; Aaron K Chamberlain; Holly M Horton; Sher Karki; Irene W L Leung; Thomas J Sproule; Greg A Lazar; Derry C Roopenian; John R Desjarlais
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

Review 7.  Neonatal Fc receptor: from immunity to therapeutics.

Authors:  Timothy T Kuo; Kristi Baker; Masaru Yoshida; Shuo-Wang Qiao; Victoria G Aveson; Wayne I Lencer; Richard S Blumberg
Journal:  J Clin Immunol       Date:  2010-10-01       Impact factor: 8.317

8.  Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Authors:  Yik Andy Yeung; Maya K Leabman; Jonathan S Marvin; Julia Qiu; Camellia W Adams; Samantha Lien; Melissa A Starovasnik; Henry B Lowman
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

9.  Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.

Authors:  Nancy A Goebl; Clifford M Babbey; Amita Datta-Mannan; Derrick R Witcher; Victor J Wroblewski; Kenneth W Dunn
Journal:  Mol Biol Cell       Date:  2008-10-08       Impact factor: 4.138

10.  Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn.

Authors:  Hai Pan; Kenneth Chen; Liping Chu; Francis Kinderman; Izydor Apostol; Gang Huang
Journal:  Protein Sci       Date:  2009-02       Impact factor: 6.725

View more
  47 in total

1.  Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.

Authors:  Austin W Boesch; James H Kappel; Alison E Mahan; Thach H Chu; Andrew R Crowley; Nana Y Osei-Owusu; Galit Alter; Margaret E Ackerman
Journal:  Biotechnol Bioeng       Date:  2018-02-01       Impact factor: 4.530

Review 2.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

3.  Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.

Authors:  L Nathan Tumey; Fengping Li; Brian Rago; Xiaogang Han; Frank Loganzo; Sylvia Musto; Edmund I Graziani; Sujiet Puthenveetil; Jeffrey Casavant; Kimberly Marquette; Tracey Clark; Jack Bikker; Eric M Bennett; Frank Barletta; Nicole Piche-Nicholas; Amy Tam; Christopher J O'Donnell; Hans Peter Gerber; Lioudmila Tchistiakova
Journal:  AAPS J       Date:  2017-04-24       Impact factor: 4.009

Review 4.  Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.

Authors:  Miroslav Dostalek; Thomayant Prueksaritanont; Robert F Kelley
Journal:  MAbs       Date:  2017-05-02       Impact factor: 5.857

5.  A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life.

Authors:  Pernille Foged Jensen; Angela Schoch; Vincent Larraillet; Maximiliane Hilger; Tilman Schlothauer; Thomas Emrich; Kasper Dyrberg Rand
Journal:  Mol Cell Proteomics       Date:  2017-01-06       Impact factor: 5.911

6.  Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.

Authors:  Claudia A Castro Jaramillo; Sara Belli; Anne-Christine Cascais; Sherri Dudal; Martin R Edelmann; Markus Haak; Marie-Elise Brun; Michael B Otteneder; Mohammed Ullah; Christoph Funk; Franz Schuler; Silke Simon
Journal:  MAbs       Date:  2017-04-25       Impact factor: 5.857

7.  Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data.

Authors:  Xiangdan Wang; Patrick McKay; Liliana T Yee; George Dutina; Philip E Hass; Ihsan Nijem; David Allison; Kyra J Cowan; Kevin Lin; Valerie Quarmby; Jihong Yang
Journal:  MAbs       Date:  2016-12-21       Impact factor: 5.857

8.  Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics.

Authors:  Lindsay B Avery; Jason Wade; Mengmeng Wang; Amy Tam; Amy King; Nicole Piche-Nicholas; Mania S Kavosi; Steve Penn; David Cirelli; Jeffrey C Kurz; Minlei Zhang; Orla Cunningham; Rhys Jones; Brian J Fennell; Barry McDonnell; Paul Sakorafas; James Apgar; William J Finlay; Laura Lin; Laird Bloom; Denise M O'Hara
Journal:  MAbs       Date:  2018-01-29       Impact factor: 5.857

Review 9.  Targeting FcRn to Generate Antibody-Based Therapeutics.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Trends Pharmacol Sci       Date:  2018-08-22       Impact factor: 14.819

10.  Target-independent variable region mediated effects on antibody clearance can be FcRn independent.

Authors:  Ryan L Kelly; Yao Yu; Tingwan Sun; Isabelle Caffry; Heather Lynaugh; Michael Brown; Tushar Jain; Yingda Xu; K Dane Wittrup
Journal:  MAbs       Date:  2016-09-09       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.